新的p-tau 217血检用于检测阿尔茨海默氏病,可能会增加Eli Lilly和生物基因保健储备。 New p-tau217 blood tests for Alzheimer's detection may boost Eli Lilly and Biogen healthcare stocks.
新的p-tau217蛋白质血液检测可以改善早期发现阿尔茨海默病, 潜在地提高医疗保健股票 Eli Lilly 和 Biogen, 已经获得FDA批准的阿尔茨海默病治疗. New blood tests for p-tau217 protein could improve early detection of Alzheimer's, potentially boosting healthcare stocks Eli Lilly and Biogen, which already have FDA-approved Alzheimer's treatments. 伊利利利的Kisunla已经证明有潜力减缓疾病进展的35%,而Biogen的Leqembi可能会在1月份获得月度注射版的批准. Eli Lilly's Kisunla has demonstrated potential to slow disease progression by 35%, and Biogen's Leqembi could see a monthly injectable version approved by January. 如果这些血液检测获得批准，可能会对医疗保健投资者的两家公司的股票产生积极影响。 These blood tests, if approved, could positively impact both companies' stocks for healthcare investors.